Over 60 years ago, scientists had began speculating that medical therapy should not be considered a generalized treatment. Too often would patients respond with varying side effects, with treatment rarely ending in widespread success. Undoubtedly, there was still much to be discovered about the relationship between host genetics and response to treatment for diseases. However, it is this drawback that has lead to modern day’s massive limelight on Personalized medicine (PM). Disease therapies can now be fine-tuned at the patient level, reducing the rate of failure to virtually zero. Though this medical model is not necessarily new, technological and computational advances have allowed PM to rapidly gain attention within the last decade. Current research on personalized medicine has opened a plethora of possibilities for both the patient and for healthcare providers in the pharmaceutical sector.
Additionally, the PM approach is cheaper and more efficient than the traditional medical care process because of its individualization, and can create more space for the budget by reducing the large amounts spent on Clinical trials (CT). At the core of PM’s ideology is the individual, represented by their DNA. There are new advances which will revolutionize the public’s understanding of the human body and expand the market. Scientists have been researching the genome and focusing on single nucleotide polymorphisms (SNPs): the gateway to good health and longevity, through the development of genetic analysis tests. Though genetic kits are still in the first stages of infancy, the possibilities are endless.
Recent comments